Short answer: No diet has been shown to prevent or slow Parkinson’s disease. In observational studies, Mediterranean eating, coffee, tea and berries are linked to lower risk, and milk to modestly higher risk. A Mediterranean-style diet is a reasonable choice. If you take levodopa, protein can blunt it, so plan meal timing with your neurologist.

No diet can prevent or cure Parkinson’s disease (PD), and none has been shown in trials to slow it. Observational studies do link some foods and patterns to lower risk: a Mediterranean diet, coffee and tea, and berries. Dairy, especially milk, is linked to a modestly higher risk. These studies can’t show that diet causes the difference, so the evidence is preliminary.

Diet is not a substitute for the treatment a neurologist prescribes. Never change the dose or timing of Parkinson’s medication without talking to your care team.

What to eat with Parkinson’s

This framework is based on observational evidence and general healthy eating. It complements medical treatment.

  • Every day: plenty of varied, deeply colored vegetables and fruit; a serving of berries; extra virgin olive oil as your main fat (3 to 4 tablespoons a day). Coffee and green tea are fine if you tolerate them and your doctor agrees.
  • Every week: fatty fish (salmon, sardines, mackerel, herring, anchovies) two to three times, and legumes three to four times. Eat fermented foods such as yogurt, kefir, sauerkraut or kimchi regularly, and nuts, especially walnuts and almonds.
  • Cut back on: ultra-processed food, saturated fat and refined sugar. Consider drinking less milk and favoring yogurt or kefir. Choosing organic produce where practical, especially for heavily sprayed crops, limits pesticide residues.
  • For constipation: enough fiber, fluids and regular physical activity are first-line steps before medication.
  • If you take levodopa: see protein and levodopa below.
  • Supplements: No supplement has been shown to slow PD. Supplements can interact with medicines, so ask your neurologist or pharmacist before taking any, including omega-3, vitamin D or coenzyme Q10. CoQ10 is biologically plausible for PD, but trials have not shown clear benefit.

What Parkinson’s does in the brain

Parkinson’s affected about 11.8 million people worldwide in 2021 (Yang 2026). It is the second most common neurodegenerative disease after Alzheimer’s. The movement symptoms (tremor, stiffness, slowness and poor balance) come from the gradual loss of dopamine-producing cells in a small area of the midbrain. By the time these symptoms appear, a large share of those cells is already gone.

Non-movement symptoms, such as constipation, loss of smell, sleep problems, depression and anxiety, often appear years or decades earlier. Oxidative stress, damaged mitochondria, inflammation and clumps of a protein called alpha-synuclein all play a part. Foods that counter these processes are of interest, and some are linked to lower PD risk, but none has been shown to slow PD in trials.

Mediterranean diet

The Mediterranean diet is rich in vegetables, fruit, legumes, whole grains, nuts, olive oil and fish, with moderate dairy and wine and little red or processed meat.

  • In a New York case-control study (Alcalay 2012), 257 people with PD and 198 controls were compared. People with PD had lower adherence to a Mediterranean-type diet (odds ratio 0.86 per point on a 9-point score), and lower scores were linked to earlier onset. Case-control studies ask about diet after diagnosis, so they can’t show which came first.
  • Yin 2021 followed more than 47,000 Swedish women. High adherence in middle age was linked to lower PD risk later in life (hazard ratio 0.54 for high versus low adherence), mainly from age 65 onward. This is observational evidence.

Olive oil contains hydroxytyrosol, which reduces oxidative stress in cell and animal models of PD. Whether this happens at food amounts is not known. The diet’s low glycemic load also reduces insulin resistance, which is increasingly linked to neurodegeneration. Our Mediterranean diet guide covers the pattern in detail.

Coffee, tea and caffeine

The link between caffeine and lower PD risk is one of the most replicated findings in PD research, though it is observational.

  • Coffee: In the Honolulu Heart Program (Ross 2000), over 8,000 Japanese-American men were followed for 30 years. PD incidence was 10.4 per 10,000 person-years in men who drank no coffee and 1.9 per 10,000 in men who drank at least 28 ounces a day. Risk fell steadily as intake rose.
  • Caffeine overall: A meta-analysis of 26 studies (Costa 2010) linked each extra 300 mg of caffeine a day (about three cups of coffee) to about 24 percent lower PD risk. The link was weaker in women.
  • Men and women: In about 47,000 men and 88,000 women (Ascherio 2001), men in the top fifth of caffeine intake had a 58 percent lower risk than men in the bottom fifth. In women the relationship was U-shaped, with the lowest risk at 1–3 cups of coffee a day.
  • Tea: A meta-analysis (Qi & Li 2014) found that each two cups of tea a day was linked to 26 percent lower PD risk. Tea also contains polyphenols such as EGCG, so caffeine may not explain all of it.

Caffeine blocks the brain’s adenosine A2A receptors, which boosts dopamine signaling. A drug that blocks the same receptor, istradefylline, is approved in Japan and the United States as an add-on PD treatment. It treats symptoms; it does not slow the disease. More in caffeine and cognition.

Healthy adults should keep caffeine below about 400 mg a day (200 mg in pregnancy).

Berries and other polyphenols

Gao 2012 followed over 130,000 people in two large US cohorts. Those in the top fifth of anthocyanin intake (the red, blue and purple pigments in berries) had about 24 percent lower PD risk than those in the bottom fifth. Berry eaters had about 23 percent lower risk. Total flavonoids were linked to lower risk only in men. This is observational evidence.

Curcumin, from turmeric, reduced alpha-synuclein clumping in a test tube and in cultured cells (Pandey 2008). It is poorly absorbed. Curcumin supplements, especially high-absorption products or those with piperine, have been linked to cases of liver injury. Avoid them with liver disease, and ask a doctor first if you take blood thinners. Turmeric as a spice in food is a different matter.

Eat a range of polyphenol-rich foods: berries, green tea, olive oil, some dark chocolate, turmeric and colorful vegetables. Whether they protect against PD in people has not been tested in trials. Our blueberries page has more on the most studied berry.

Fatty fish and omega-3s

In mice fed a high omega-3 diet for 10 months (Bousquet 2008), the fats protected against a toxin that kills dopamine cells. In people, evidence is limited. In 5,289 people from the Rotterdam Study (de Lau 2005), higher intake of total, monounsaturated and polyunsaturated fat was linked to lower PD risk. The analysis rested on only 51 cases.

Eating fatty fish two to three times a week fits general healthy-eating advice; it has not been shown to protect against PD. There is no trial evidence that fish oil helps in PD.

Fish oil can increase bleeding risk with anticoagulant or antiplatelet drugs. In trials, doses above about 1 g a day have been linked to a higher risk of atrial fibrillation. Ask a doctor or pharmacist before starting any supplement.

The gut and Parkinson’s

PD may involve the gut early on. Diet strongly shapes gut bacteria, but whether changing them through diet affects PD has not been shown.

  • Constipation comes first: Abbott 2001 followed 6,790 men from the Honolulu Heart Program for 24 years. Men with less than one bowel movement a day had a 2.7-fold higher risk of PD than men with one a day. Constipation may be an early part of the disease or a marker of other risks.
  • Gut origin hypothesis: Braak 2003 found that Lewy pathology (the alpha-synuclein clumps typical of PD) appears first in a vagus nerve center in the brainstem and in a smell center. It then spreads upward through the brain. His group proposed that PD may start in the gut or the nose. This is debated.
  • Evidence for it: Shannon 2012 found alpha-synuclein in old colon biopsies from three people, taken 2 to 5 years before their first movement symptoms, and in none of 23 controls. In Danish registry data (Svensson 2015), cutting the vagus nerve did not clearly lower PD risk overall, but after more than 20 years the risk was about half. Precision was limited. In mice (Kim 2019), alpha-synuclein injected into the gut spread to the brain through the vagus nerve, and cutting the nerve prevented this.
  • Different gut bacteria: In 72 patients and 72 controls (Scheperjans 2015), a bacterial family called Prevotellaceae was 77.6 percent less abundant in PD. Later studies have found fewer bacteria that make short-chain fatty acids, which help keep the gut barrier intact.

A diet rich in varied fiber, fermented foods and polyphenols supports these helpful bacteria and eases constipation. Our gut-brain axis guide explains more.

Urate

Urate (uric acid) is an antioxidant in the blood. Higher levels raise the risk of gout and kidney stones, but they are also linked to lower PD risk and slower progression.

In a nested case-control study of 84 cases (Weisskopf 2007), men with the highest urate had a lower PD risk than those with the lowest (rate ratio 0.43). The confidence interval included no effect, though the trend across groups was significant. In about 800 people with early PD (Ascherio 2009), those with the highest urate had a 36 percent lower rate of reaching disability that needed levodopa.

But raising urate did not help. In the SURE-PD3 trial (Parkinson Study Group SURE-PD3 Investigators 2021), inosine raised urate in 298 people with early PD but did not slow progression. Don’t try to raise urate through diet: purine-rich foods and fructose raise it, along with the risk of gout and kidney stones, and the benefit is unproven.

Dairy

Dairy is one of the few foods linked to higher rather than lower PD risk.

  • In the Cancer Prevention Study II Nutrition Cohort (Chen 2007), higher dairy intake was linked to a modestly higher PD risk in both men and women. The relative risk was 1.6 for the top versus bottom fifth.
  • A meta-analysis of seven prospective results (Jiang 2014) found about 40 percent higher risk with high dairy intake. The link was clear for milk, weaker for cheese and absent for yogurt. It was seen in men but not clearly in women.

In absolute terms, the meta-analysis estimated 2 to 4 extra PD cases per 100,000 people per year for each extra 200 g of milk a day. The cause is debated: proposals include pesticide residues in animal fat and dairy lowering urate.

Cutting out dairy is not warranted. If you are at higher risk (a family history or early symptoms), drinking less milk and favoring yogurt or kefir is a possible precaution. If you cut back on dairy, keep calcium and vitamin D intake adequate.

Protein and levodopa

Levodopa is the most effective PD medication. It travels from the gut into the blood, and on into the brain, using the same carriers as some amino acids from dietary protein. A protein-rich meal around the time of a dose competes with levodopa, so less reaches the brain. This can cause “wearing off” or unpredictable on/off swings in movement.

In nine patients with on-off swings (Nutt 1984), meals reduced and delayed levodopa absorption, and high-protein meals or certain amino acids reversed the effect of levodopa given by infusion.

What helps:

  • Separate doses from protein-rich meals. Your neurologist or pharmacist can advise on timing for your medication and formulation.
  • If that is not enough, some people move most of their protein to the evening meal and keep daytime meals low in protein. In an uncontrolled study of 16 patients with levodopa-resistant “off” periods (Pincus & Barry 1988), putting nearly all protein in the evening meal restored levodopa response in 88 percent.
  • Keep total protein adequate. Redistribution changes timing, not the total. The general adult reference is 0.8 grams per kilogram of body weight. Too little protein leads to muscle and weight loss, which worsen mobility and fall risk.

Not everyone needs this. In early disease, when swings are minimal, normal protein through the day is usually fine. Agree any change to protein timing, or to when you take levodopa, with your neurologist and ideally a dietitian.

Frequently Asked Questions

How much coffee should I drink to protect against Parkinson’s?

No amount is proven to protect; the evidence is observational. In a meta-analysis, the link with lower risk leveled off at about 3 cups a day. Too much caffeine can cause anxiety, insomnia, stomach upset and palpitations. If you have PD, ask your doctor, since caffeine can worsen sleep problems and interacts with some medicines.

Sources

  • Yang, R., Sun, M., Chen, W., et al. (2026). Global, regional and national burden of Parkinson’s disease, 1990-2021: Update from the GBD 2021 study. Journal of the Neurological Sciences, 480, 125703. doi:10.1016/j.jns.2025.125703

  • Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24(2), 197–211. doi:10.1016/s0197-4580(02)00065-9

  • Ross, G. W., Abbott, R. D., Petrovitch, H., et al. (2000). Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA, 283(20), 2674–2679. doi:10.1001/jama.283.20.2674

  • Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001). Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Annals of Neurology, 50(1), 56–63. doi:10.1002/ana.1052

  • Costa, J., Lunet, N., Santos, C., Santos, J., & Vaz-Carneiro, A. (2010). Caffeine exposure and the risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies. Journal of Alzheimer’s Disease, 20(Suppl 1), S221–S238. doi:10.3233/JAD-2010-091525

  • Qi, H., & Li, S. (2014). Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s disease. Geriatrics and Gerontology International, 14(2), 430–439. doi:10.1111/ggi.12123

  • Alcalay, R. N., Gu, Y., Mejia-Santana, H., Cote, L., Marder, K. S., & Scarmeas, N. (2012). The association between Mediterranean diet adherence and Parkinson’s disease. Movement Disorders, 27(6), 771–774. doi:10.1002/mds.24918

  • Yin, W., Löf, M., Pedersen, N. L., Sandin, S., & Fang, F. (2021). Mediterranean dietary pattern at middle age and risk of Parkinson’s disease: A Swedish cohort study. Movement Disorders, 36(1), 255–260. doi:10.1002/mds.28314

  • Jiang, W., Ju, C., Jiang, H., & Zhang, D. (2014). Dairy foods intake and risk of Parkinson’s disease: a dose-response meta-analysis of prospective cohort studies. European Journal of Epidemiology, 29(9), 613–619. doi:10.1007/s10654-014-9921-4

  • Gao, X., Cassidy, A., Schwarzschild, M. A., Rimm, E. B., & Ascherio, A. (2012). Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology, 78(15), 1138–1145. doi:10.1212/WNL.0b013e31824f7fc4

  • Weisskopf, M. G., O’Reilly, E., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2007). Plasma urate and risk of Parkinson’s disease. American Journal of Epidemiology, 166(5), 561–567. doi:10.1093/aje/kwm127

  • Ascherio, A., LeWitt, P. A., Xu, K., et al. (2009). Urate as a predictor of the rate of clinical decline in Parkinson disease. Archives of Neurology, 66(12), 1460–1468. doi:10.1001/archneurol.2009.247

  • Parkinson Study Group SURE-PD3 Investigators; Schwarzschild, M. A., Ascherio, A., et al. (2021). Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial. JAMA, 326(10), 926–939. doi:10.1001/jama.2021.10207

  • Abbott, R. D., Petrovitch, H., White, L. R., et al. (2001). Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology, 57(3), 456–462. doi:10.1212/wnl.57.3.456

  • Shannon, K. M., Keshavarzian, A., Dodiya, H. B., Jakate, S., & Kordower, J. H. (2012). Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases. Movement Disorders, 27(6), 716–719. doi:10.1002/mds.25020

  • Svensson, E., Horváth-Puhó, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., & Sørensen, H. T. (2015). Vagotomy and subsequent risk of Parkinson’s disease. Annals of Neurology, 78(4), 522–529. doi:10.1002/ana.24448

  • Kim, S., Kwon, S. H., Kam, T. I., et al. (2019). Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron, 103(4), 627–641.e7. doi:10.1016/j.neuron.2019.05.035

  • Scheperjans, F., Aho, V., Pereira, P. A., et al. (2015). Gut microbiota are related to Parkinson’s disease and clinical phenotype. Movement Disorders, 30(3), 350–358. doi:10.1002/mds.26069

  • Bousquet, M., Saint-Pierre, M., Julien, C., Salem, N., Jr., Cicchetti, F., & Calon, F. (2008). Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson’s disease. The FASEB Journal, 22(4), 1213–1225. doi:10.1096/fj.07-9677com

  • de Lau, L. M., Bornebroek, M., Witteman, J. C., Hofman, A., Koudstaal, P. J., & Breteler, M. M. (2005). Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology, 64(12), 2040–2045. doi:10.1212/01.WNL.0000166038.67153.9F

  • Chen, H., O’Reilly, E., McCullough, M. L., et al. (2007). Consumption of dairy products and risk of Parkinson’s disease. American Journal of Epidemiology, 165(9), 998–1006. doi:10.1093/aje/kwk089

  • Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H., & Anderson, J. L. (1984). The “on-off” phenomenon in Parkinson’s disease: relation to levodopa absorption and transport. New England Journal of Medicine, 310(8), 483–488. doi:10.1056/NEJM198402233100802

  • Pincus, J. H., & Barry, K. (1988). Protein redistribution diet restores motor function in patients with dopa-resistant “off” periods. Neurology, 38(3), 481–483. doi:10.1212/wnl.38.3.481

  • Pandey, N., Strider, J., Nolan, W. C., Yan, S. X., & Galvin, J. E. (2008). Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathologica, 115(4), 479–489. doi:10.1007/s00401-007-0332-4